Plain-English translation of NCT06444880 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new medication called to see if it can treat rare, aggressive cancers (including a type of kidney cancer and a soft tissue cancer) that have a specific genetic change and have stopped responding to prior treatments. Researchers want to learn whether this medication works better on its own or when combined with another immunotherapy drug called .
These rare cancers are very hard to treat and patients often run out of options after their first treatment fails. This medication targets a specific marker on cancer cells, which may help the body's immune system fight back against these aggressive tumors.
You likely qualify if…
You likely don't qualify if…
You will receive infusions of the medication into your vein, starting with once a week for the first month, then every three weeks after that. If your cancer gets worse after six weeks, you will move to the second stage and receive a combination of two medications. The research team will monitor you closely with blood tests and imaging scans to see how your cancer responds and watch for any side effects.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
United States
Phase
Testing effectiveness
Sponsor
M.D. Anderson Cancer Center
Collaborators
Regeneron Pharmaceuticals
Enrollment target
~40 participants
Started
October 2024
Primary completion
July 2028
Age range
12 Years and older
Last updated on clinicaltrials.gov in June 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pavlos Msaouel, MD,PHD,PHD
M.D. Anderson Cancer Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.